BiotechTube

Placebo + Dose 1 gevokizumab + Dose 2 gevokizumab

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uveitis

Conditions

Uveitis

Trial Timeline

Aug 1, 2012 → —

NCT ID
NCT01684345

About Placebo + Dose 1 gevokizumab + Dose 2 gevokizumab

Placebo + Dose 1 gevokizumab + Dose 2 gevokizumab is a phase 3 stage product being developed by XOMA for Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01684345. Target conditions include Uveitis.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis were approved

Approved (3) Terminated (8) Active (9)
✅Ixekizumab Prefilled SyringeEli LillyApproved
✅AdalimumabAbbVieApproved
✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved
🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
🔄Baricitinib + AdalimumabEli LillyPhase 3
🔄adalimumabAbbViePhase 3
🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01747538Phase 3Terminated
NCT01684345Phase 3Terminated

Competing Products

20 competing products in Uveitis

See all competitors
ProductCompanyStageHype Score
triamcinolone acetonide (Triesence®)Clearside BiomedicalPhase 1/2
22
4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
30
Baricitinib + AdalimumabEli LillyPhase 3
44
Ixekizumab Prefilled SyringeEli LillyApproved
39
adalimumabAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
AdalimumabAbbVieApproved
43
FTY720 + Oral CorticosteroidNovartisPhase 2
27
AIN457NovartisPhase 3
32
MyforticNovartisPre-clinical
22
AIN457 + AIN457 + Placebo AIN457NovartisPhase 3
32
LFG316 + Conventional TherapyNovartisPhase 2
35
RanibizumabNovartisPhase 2
35
AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
AEB071NovartisPhase 2
35
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
Myfortic + DecortinNovartisPhase 3
40
AIN457 + AIN 457 + AIN457NovartisPhase 2
35